Combination Cancer Therapy is Focus of $1M Merck & Co., Inc. Research Grant Received by National Comprehensive Cancer Network

Busineswire -- NCCN has been awarded a $1M research grant from Merck & Co, Inc., that will support research of the anti-cancer agent vorinostat (Zolinza®). Vorinostat is currently used to treat progressive, persistent, or recurrent cutaneous T-cell lymphoma. This research grant will fund studies to explore the efficacy of vorinostat in combination with chemotherapy and/or radiation therapy in selected locally advanced non-metastatic cancers including non-small cell lung cancer, head and neck cancer, pancreatic adenocarcinoma, and brain metastases from a solid tumor with an emphasis on lung cancer.

Back to news